New eye drug regimen aims to cut injection frequency for PCV patients
NCT ID NCT07461441
First seen Mar 26, 2026 · Last updated Jun 21, 2026 · Updated 13 times
Summary
This Phase 3 trial is testing faricimab (Vabysmo) in 50 people with a specific form of wet age-related macular degeneration called polypoidal choroidal vasculopathy (PCV). The goal is to see if a personalized treat-and-extend schedule can maintain vision while allowing longer gaps between injections. Participants will receive faricimab injections into the eye, with the interval between doses adjusted based on their response, up to 96 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Yeungnam university medical center
RECRUITINGDaegu, Namgu, 42415, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
faricimab (Vabysmo) injection
What this could lead to
If successful, this could offer a personalized treatment schedule for PCV that extends time between injections, reducing the burden of frequent eye injections.
What could go wrong
This is a small Phase 3 trial (50 participants) and results may not apply to all PCV patients. Faricimab is already approved for other eye conditions, but its long-term durability and safety in this specific regimen are still being tested.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.